טוען...
Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report
Available data on switching from originator infliximab to CT‐P13 in patients with inflammatory bowel disease are reassuring regarding safety and efficacy outcomes. However, monitoring of such patients, especially in the early phase after switching, is important given the possibility that rare side e...
שמור ב:
| הוצא לאור ב: | Clin Case Rep |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6878056/ https://ncbi.nlm.nih.gov/pubmed/31788249 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.2394 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|